This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
World Health Organization. Country Cooperation Strategy for WHO and Egypt 2010–2014. Cairo, Egypt: World Health Organization Regional Office for the Eastern Mediterranean, 2010. Available from http://who.int/countryfocus/cooperation_strategy/ccs_egy_en.pdf?ua=1 (accessed October 2016).World Health Organization. Country Cooperation Strategy for WHO and Egypt 2010–2014Cairo, EgyptWorld Health Organization Regional Office for the Eastern Mediterranean2010Available fromhttp://who.int/countryfocus/cooperation_strategy/ccs_egy_en.pdf?ua=1accessed October 2016Search in Google Scholar
World Federation of Hemophilia. Guidelines for the management of hemophilia. 2nd edition. 2012. Available from https://www1.wfh.org/publications/files/pdf-1472.pdf (accessed 24 September 2018).World Federation of Hemophilia. Guidelines for the management of hemophilia. 2nd edition2012Available fromhttps://www1.wfh.org/publications/files/pdf-1472.pdfaccessed 24 September 2018Search in Google Scholar
Kabil N, ElAlfy MS, Metwalli N. Evaluation of the oral health situation of a group of Egyptian haemophilic children and their re-evaluation following an oral hygiene and diet education programme. Haemophilia 2007;13:287–92.KabilNElAlfyMSMetwalliNEvaluation of the oral health situation of a group of Egyptian haemophilic children and their re-evaluation following an oral hygiene and diet education programmeHaemophilia2007132879210.1111/j.1365-2516.2007.01440.x17498078Search in Google Scholar
Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al; Treatment Guidelines Working Group on Behalf of the World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1–e47.SrivastavaABrewerAKMauser-BunschotenEPet alTreatment Guidelines Working Group on Behalf of the World Federation of Hemophilia. Guidelines for the management of hemophiliaHaemophilia201319e1e4710.1111/j.1365-2516.2012.02909.x22776238Search in Google Scholar
Lobet S, Hermans C, Lambert C. Optimal management of hemophilic arthropathy and hematomas. J Blood Med 2014: 5; 207–18.LobetSHermansCLambertCOptimal management of hemophilic arthropathy and hematomasJ Blood Med201452071810.2147/JBM.S50644420758525378964Search in Google Scholar
El-Zanaty F, Way A. Egypt Demographic and Health Survey 2008 Cairo, Egypt: Ministry of Health, El-Zanaty and Associates, and Macro International, 2009. Available from https://dhsprogram.com/pubs/pdf/fr220/fr220.pdf (accessed 24 September 2018).El-ZanatyFWayAEgypt Demographic and Health Survey 2008Cairo, EgyptMinistry of Health, El-Zanaty and Associates, and Macro International2009Available fromhttps://dhsprogram.com/pubs/pdf/fr220/fr220.pdfaccessed 24 September 2018Search in Google Scholar
Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis 2013; 13: 288.MohamoudYAMumtazGRRiomeSMillerDAbu-RaddadLJThe epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesisBMC Infect Dis20131328810.1186/1471-2334-13-288370243823799878Search in Google Scholar
El Ekiaby M, Moftah F, Goubran H, et al. Viremia levels in hepatitis C infection among Egyptian blood donors and implications for transmission risk with different screening scenarios. Transfusion 2015; 55: 1186–94.ElEkiaby MMoftahFGoubranHet alViremia levels in hepatitis C infection among Egyptian blood donors and implications for transmission risk with different screening scenariosTransfusion20155511869410.1111/trf.1306125766141Search in Google Scholar
Cassis FR, Querol F, Forsyth A, Iorio A, HERO International Advisory Board. Psychosocial aspects of haemophilia: a systematic review of methodologies and findings. Haemophilia 2012; 18: e101–14.CassisFRQuerolFForsythAIorioAHERO International Advisory Board. Psychosocial aspects of haemophilia: a systematic review of methodologies and findingsHaemophilia201218e1011410.1111/j.1365-2516.2011.02683.x22059839Search in Google Scholar
Tantawy A, von Mackenssen S, Mohammed AM, et al. Health-related quality of life in Egyptian children and adolescents with hemophilia A. Pediatr Hematol Oncol 2011; 28: 222–9.TantawyAvon MackenssenSMohammedAMet alHealth-related quality of life in Egyptian children and adolescents with hemophilia APediatr Hematol Oncol201128222910.3109/08880018.2010.53511621271776Search in Google Scholar
Bottos AM, Zanon E, Sartori MT, Girolami A. Psychological aspects and coping styles of parents with haemophilic child undergoing a programme of counselling and psychological support. Haemophilia 2007; 13: 305–10.BottosAMZanonESartoriMTGirolamiAPsychological aspects and coping styles of parents with haemophilic child undergoing a programme of counselling and psychological supportHaemophilia2007133051010.1111/j.1365-2516.2006.01428.x17498080Search in Google Scholar
Zulfikar B, Karaman MI, Ovali F. Circumcision in hemophilia: an overview. 2003. Available from www1.wfh.org/publication/files/pdf-1170.pdf (accessed October 2016).ZulfikarBKaramanMIOvaliFCircumcision in hemophilia: an overview2003Available fromwww1.wfh.org/publication/files/pdf-1170.pdfaccessed October 2016Search in Google Scholar
Elalfy MS, Elbarbary NS, Eldebeiky MS, El Danasoury AS. Risk of bleeding and inhibitor development after circumcision of previously untreated or minimally treated severe hemophilia A children. Pediatr Hematol Oncol 2012; 29: 485–93.ElAlfyMSElbarbaryNSEldebeikyMSEl DanasouryASRisk of bleeding and inhibitor development after circumcision of previously untreated or minimally treated severe hemophilia A childrenPediatr Hematol Oncol2012294859310.3109/08880018.2012.70462422866674Search in Google Scholar
Paisley S, Wight J, Currie E, Knight C. The management of inhibitors in haemophilia A: introduction and systematic review of current practice. Haemophilia 2003; 9: 405–17.PaisleySWightJCurrieEKnightCThe management of inhibitors in haemophilia A: introduction and systematic review of current practiceHaemophilia200394051710.1046/j.1365-2516.2003.00779.x12828677Search in Google Scholar
Rivard GE, Rothschild C, Toll T, Achilles K. Immune tolerance induction in haemophilia A patients with inhibitors by treatment with recombinant factor VIII: a retrospective non-interventional study. Haemophilia 2013; 19: 449–55.RivardGERothschildCTollTAchillesKImmune tolerance induction in haemophilia A patients with inhibitors by treatment with recombinant factor VIII: a retrospective non-interventional studyHaemophilia2013194495510.1111/hae.12102Search in Google Scholar
European Medicines Agency. Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products. EMA/CHMP/BPWP/144533/2009. Available from https://www.ema.europa.eu/documents/scientific-guideline/guideline-clinical-investigation-recombinant-human-plasma-derived-factor-viii-products-first-version_en.pdf (accessed 4 October 2018)..European Medicines Agency. Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products. EMA/CHMP/BPWP/144533/2009Available fromhttps://www.ema.europa.eu/documents/scientific-guideline/guideline-clinical-investigation-recombinant-human-plasma-derived-factor-viii-products-first-version_en.pdfaccessed 4 October2018Search in Google Scholar
Iorio A, Puccetti P, Makris M. Clotting factor concentrate switching and inhibitor development in hemophilia A. Blood 2012; 120: 720–27.IorioAPuccettiPMakrisMClotting factor concentrate switching and inhibitor development in hemophilia ABlood20121207202710.1182/blood-2012-03-378927Search in Google Scholar
Marcucci M, Mancuso ME, Santagostino E, et al. Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis. Thromb Haemost 2015; 113: 958–67.MarcucciMMancusoMESantagostinoEet alType and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysisThromb Haemost20151139586710.1160/TH14-07-0621Search in Google Scholar
Di Minno G, Canaro M, Ironside JW, et al. Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice. Haematologica 2013; 98: 1495–98.DiMinno GCanaroMIronsideJWet alPathogen safety of long-term treatments for bleeding disorders: still relevant to current practiceHaematologica20139814959810.3324/haematol.2013.084145Search in Google Scholar
Di Minno G, Canaro M, Ironside JW, et al. Pathogen safety of long-term treatments for bleeding disorders: (un)predictable risks and evolving threats. Semin Thromb Haemost 2013; 39: 779–93.DiMinno GCanaroMIronsideJWet alPathogen safety of long-term treatments for bleeding disorders: (un)predictable risks and evolving threatsSemin Thromb Haemost2013397799310.1055/s-0033-1354420Search in Google Scholar
Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet 2007; 370: 439–48.KeyNSNegrierCCoagulation factor concentrates: past, present, and futureLancet20073704394810.1016/S0140-6736(07)61199-4Search in Google Scholar
Abdel-Messih IY, Habashy DM, Moftah SG, ElAlfy MS. Persistent factor VIII inhibitors and orthopaedic complications in children with severe haemophilia A. Haemophilia 2011; 17: 490–3.Abdel-MessihIYHabashyDMMoftahSGElAlfyMSPersistent factor VIII inhibitors and orthopaedic complications in children with severe haemophilia AHaemophilia201117490310.1111/j.1365-2516.2010.02447.x21371185Search in Google Scholar
Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med 2016; 374: 2054–64.PeyvandiFMannucciPMGaragiolaIet alA randomized trial of factor VIII and neutralizing antibodies in hemophilia AN Engl J Med201637420546410.1056/NEJMoa151643727223147Search in Google Scholar
Makris M. Prophylaxis in haemophilia should be life-long. Blood Transfus 2012; 10: 165–8.MakrisMProphylaxis in haemophilia should be life-longBlood Transfus2012101658Search in Google Scholar
Fischer K, van der Bom JG, Molho P, et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002; 8: 745–52.FischerKvan derBom JGMolhoPet alProphylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcomeHaemophilia200287455210.1046/j.1365-2516.2002.00695.x12410642Search in Google Scholar
Elekiaby A, El Saied H, Elekiaby M. Five years of tailored low dose prophylaxis in a small cohort of kids with severe hemophilia A using SD-F cryoprecipitate. Poster no. PO169 presented at the World Federation of Hemophilia Congress; 24-28 July 2016; Orlando, FL.ElekiabyAEl SaiedHElekiabyMFive years of tailored low dose prophylaxis in a small cohort of kids with severe hemophilia A using SD-F cryoprecipitate. Poster no. PO169 presented at the World Federation of Hemophilia Congress24-28 July2016Orlando, FLSearch in Google Scholar
El-Kiaby M, Goubran HA, Radosevich M, et al. Pharmacokinetic study of minipooled solvent/detergent filtered cryoprecipitate factor VIII. Haemophilia 2011; 17: e884–8.El-KiabyMGoubranHARadosevichMet alPharmacokinetic study of minipooled solvent/detergent filtered cryoprecipitate factor VIIIHaemophilia201117e884810.1111/j.1365-2516.2011.02511.x21371202Search in Google Scholar
BeneFIX: Summary of product characteristics, 2016.BeneFIX: Summary of product characteristics2016Search in Google Scholar
Rodriguez-Merchan EC. Methods to treat chronic haemophilic synovitis. Haemophilia 2001; 7: 1–5.Rodriguez-MerchanEC.Methods to treat chronic haemophilic synovitisHaemophilia2001715Search in Google Scholar
Rodriguez-Merchan EC, Caviglia HA, Magallon M, Perez-Bianco R. Chemical synovectomy vs. radioactive synovectomy for the treatment of chronic haemophilic synovitis: a prospective short- term study. Haemophilia 1997; 3: 118–22.Rodriguez-MerchanECCavigliaHAMagallonMPerez-BiancoRChemical synovectomy vs. radioactive synovectomy for the treatment of chronic haemophilic synovitis: a prospective short- term studyHaemophilia199731182210.1046/j.1365-2516.1997.00080.x27214721Search in Google Scholar
